However, cell lines with high PSILC score were frequently PTEN inactivated and/or harboured an ERBB2 amplification (PPTEN = 0.007, PERBB2 = 0.002, Fig. 5b, c; Welch’s t-test), both of which are known features of aggressive breast cancers [51, 52] and ERBB2-targeted therapies are already in clinical use [53]. This evidence concerns the gene PTEN and breast cancer.